Kantor O - Search Results

1

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.

Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Losk K, et al. Among authors: kantor o. Breast Cancer Res Treat. 2021 Jan;185(1):215-227. doi: 10.1007/s10549-020-05931-9. Epub 2020 Sep 16. Breast Cancer Res Treat. 2021. PMID: 32939592

2

The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer.

Ajmani GS, James TA, Kantor O, Wang CH, Yao KA. Ajmani GS, et al. Among authors: kantor o. Ann Surg Oncol. 2017 Oct;24(11):3157-3166. doi: 10.1245/s10434-017-5969-1. Epub 2017 Jul 6. Ann Surg Oncol. 2017. PMID: 28685357

3

A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.

Kantor O, Sipsy LM, Yao K, James TA. Kantor O, et al. Ann Surg Oncol. 2018 May;25(5):1304-1311. doi: 10.1245/s10434-018-6345-5. Epub 2018 Jan 24. Ann Surg Oncol. 2018. PMID: 29368152

4

Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging.

Kantor O, Niu J, Zhao H, Giordano SH, Hunt KK, King TA, Mittendorf EA, Chavez-MacGregor M. Kantor O, et al. Ann Surg Oncol. 2020 Jul;27(7):2229-2237. doi: 10.1245/s10434-019-08169-y. Epub 2020 Jan 8. Ann Surg Oncol. 2020. PMID: 31916091

5

Baseline Screening MRI Uptake and Findings in Women with ≥ 20% Lifetime Risk of Breast Cancer.

Laws A, Mulvey TM, Jalbert N, Dalton S, Kantor O, Harris KA, Krag KJ, Walsh EP, Coopey SB. Laws A, et al. Among authors: kantor o. Ann Surg Oncol. 2020 Oct;27(10):3595-3602. doi: 10.1245/s10434-020-08853-4. Epub 2020 Jul 18. Ann Surg Oncol. 2020. PMID: 32683633

6

Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.

Laws A, Dillon K, Kelly BN, Kantor O, Hughes KS, Gadd MA, Smith BL, Lamb LR, Specht M. Laws A, et al. Among authors: kantor o. Ann Surg Oncol. 2020 Nov;27(12):4819-4827. doi: 10.1245/s10434-020-08902-y. Epub 2020 Aug 1. Ann Surg Oncol. 2020. PMID: 32740737

7

Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer.

Minami CA, Kantor O, Weiss A, Nakhlis F, King TA, Mittendorf EA. Minami CA, et al. Among authors: kantor o. J Am Coll Surg. 2020 Oct;231(4):434-447.e2. doi: 10.1016/j.jamcollsurg.2020.06.021. Epub 2020 Aug 6. J Am Coll Surg. 2020. PMID: 32771654 Free PMC article.

8

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.

Kantor O, Wong S, Weiss A, Metzger O, Mittendorf EA, King TA. Kantor O, et al. NPJ Breast Cancer. 2020 Aug 13;6:35. doi: 10.1038/s41523-020-00177-6. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32821803 Free PMC article.

9

Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.

Kantor O, Wakeman M, Weiss A, Wong S, Laws A, Grossmith S, Mittendorf EA, King TA. Kantor O, et al. Ann Surg Oncol. 2021 Mar;28(3):1358-1367. doi: 10.1245/s10434-020-09073-6. Epub 2020 Aug 31. Ann Surg Oncol. 2021. PMID: 32869154

10

Kelly BN, Kantor O, Tang R, Coopey SB, Smith BL, Lanahan CR, Korotkin JE, Specht MC. Kelly BN, et al. Among authors: kantor o. Breast Cancer Res Treat. 2021 Apr;186(3):807-814. doi: 10.1007/s10549-020-06026-1. Epub 2020 Nov 28. Breast Cancer Res Treat. 2021. PMID: 33247799

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters